"Eli Lilly sues Mochi Health and others for ‘deceptive’ tirzepatide marketing" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

Eli Lilly & Co.’s experimental weight-loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s ...

Eli Lilly has spent recent years reintroducing itself to the public via a series of corporate campaigns, and its latest push goes a step further.

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, including with its GLP-1 medications.

Eli Lilly stock (NYSE: LLY) is gaining momentum on Thursday, April 17th, following the company’s announcement of successful results from the first of its late-stage trials for a daily obesity ...

Has Eli Lilly's stock indeed peaked, and could this be the start of a much broader sell-off, or is now a potentially good time to add the healthcare giant to your portfolio?

Eli Lilly & Co.'s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug's blockbuster potential in the company's ...

Eli Lilly & Co.’s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s ...